Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cicletanine SCHEMBL16859315 | 1.00 | MEN1 (0.36) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL637073 | 1.00 | MEN1 (0.36) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL6060344 | 1.00 | MEN1 (0.36) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL637385 | 1.00 | MEN1 (0.36) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL29915570 | 1.00 | MEN1 (0.36) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL387011 | 0.99 | KDM4E (0.35) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL29633447 | 0.99 | KDM4E (0.35) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL1649704 | 0.97 | KDM4E (0.35) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| Cicletanine SCHEMBL6479989 | 0.94 | MEN1 (0.35) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL3798183 | 0.86 | KDM4E (0.36) | MEN1KMT2AKDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| EP-3643298-A1 | IN SITU PHASE CHANGE GEL SUSTAINED-RELEASE SYSTEM FOR SMALL MOLECULE DRUG AND PREPARATION METHOD THEREOF | Sichuan University (CN) | 2020-04-29 | — | — | EP | claimed |
| US-20200069583-A1 | IN SITU PHASE CHANGE GEL SUSTAINED-RELEASE SYSTEM FOR SMALL MOLECULE DRUG AND PREPARATION METHOD THEREOF | SICHUAN UNIVERSITY (CN) | 2020-03-05 | — | — | US | claimed |
| US-20190167632-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | MUELLER WOLFGANG S (US) | 2019-06-06 | — | — | US | claimed |
| US-10238622-B2 | Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2019-03-26 | — | — | US | claimed |
| US-20180118773-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | THERACOSBIO, LLC | 2018-05-03 | — | — | US | claimed |
| US-20170056380-A1 | Systems, Methods, Techniques, and Compounds in Research and Treatment of Portal Hypertension and other Conditions | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2017-03-02 | — | — | US | claimed |
| US-9522138-B2 | Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2016-12-20 | — | — | US | claimed |
| WO-2016109361-A2 | 3-FLUORO-BENZONITRILE INHIBITORS OF 11-BETA-HYDROXYLASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | claimed |
| CN-105641674-A | Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof | 李华红 | 2016-06-08 | — | — | CN | claimed |
| WO-2005009446-A1 | COMBINATION THERAPIES FOR TREATMENT OF HYPERTENSION AND COMPLICATIONS IN PATIENTS WITH DIABETES OR METABOLIC SYNDROME | COTHERIX, INC. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2004091612-A1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION COMPRISING CICLETANINE FOR THE PREVENTION OR TREATMENT OF DIABETES | SynoSens Kutató és Fejlesztő Kft. (HU) | 2004-10-28 | — | — | WO | claimed |
| WO-2004091632-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN ACTIVE AGENT HAVING THE EFFECT OF DIGITALIS AND A CGMP PHOSPHODIESTERASE INHIBITOR | SynoSens Kutató és Fejlesztő Kft. (HU) | 2004-10-28 | — | — | WO | claimed |
| US-6653336-B1 | Such as indapamide and tert-butylamine salt of perindopril | LES LABORATOIRES SERVIER (FR) | 2003-11-25 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0337858-B1 | Stereo-specific process for the preparation of enantiomers of furo[3,4-c]pyridine, compounds thus obtained and therapeutical compositions based on these compounds | SOD CONSEILS RECH APPLIC (FR) | 1994-06-08 | — | — | EP | claimed |
| US-5026855-A | Hypotensive agents, diuretics | SOCIETE DE CONSELS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1991-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | MEN1 2447/4885KMT2A 4250/4885KDM4E 2350/4885 |
| US-20180118773-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | SLC5A2, SLC5A1, SLC2A4 | MEN1 3974/4885KMT2A 1390/4885KDM4E 1882/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | MEN1 1866/4885KMT2A 2686/4885KDM4E 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.